Post My Press Release

Free Press Release Distribution

Category: healthcare (Page 1 of 817)

Paediatric Vaccine Market Growing Demand, Competition, Investment Opportunities & Forecast 2026

According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016.

Paediatric vaccine market is a billion dollar market accounting for a substantial proportion of healthcare expenditure in the recent times. The paediatric vaccine market is segmented according to indication, technology and vaccine type. According to the indication, the paediatric vaccine market is sub segmented into pneumococcal, DTP, rotavirus, influenza, meningococcal, hepatitis B, Hib, MMR and polio. According to technology the market is further segmented into live or attenuated, inactivated or killed, toxoid, conjugate, subunit and recombinant vaccines. By vaccine type, the global paediatric vaccine market is segmented into monovalent and multivalent vaccines.

A slew of routine immunisation initiatives rolled out by the government and private agencies has broadened the market for the paediatric vaccines. A new wave of funds pumped into the market by different government and private players to cork the rise of the child deaths across the globe has also opened a new window of opportunity for the paediatric vaccine market. As per the report of WHO (World Health Organization), the global spending on immunisation soared from US$21.4 to US$26.9 per infant in 2014. The massive economic boom in some regions of the world is expediting the growth of the paediatric vaccine market.

Segmentation analysis

  • By indication, pneumococcal segment accounted for higher revenue share in global paediatric vaccines as compared to other product segments. The pneumococcal segment is expected to reach a value of US$ 31.58 Bn by 2026, reflecting a CAGR of 14.4% over the forecast period. The growth of pneumococcal segment is attributed to the increasing incidence of infectious diseases.
  • In terms of revenue, Hib vaccine segment is the second most growing segment and is expected to reach a value of US$ 13.49 Bn by 2026, growing at a CAGR of 13.4%. Hepatitis B and meningococcal segment are expected to show double-digit CAGR growth in the forecast period contributing to the growth of global paediatric vaccine market.

Request Sample Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1317  

  • By technology, conjugate segment accounted for highest revenue share in global paediatric vaccine market as compared to live or attenuated segment. The conjugate segment is expected to reach a value of US$ 32.09 Bn by 2026, reflecting a CAGR of 14.8% over the forecast period. This is expected to be closely followed by the growth of pneumococcal and meningococcal vaccines in this segment
  • By end user, institutional health centres account for higher demand for paediatric vaccine as compared to other end user segments such as hospital pharmacies and retail pharmacies. The strong growth in institutional health centres can be attributed to increasing government interventions in immunisation programs in order to improve vaccine coverage. Institutional health centres are expected to register highest CAGR of 13.8% over the forecast period.

Regional analysis

By region, North America is dominating the global paediatric vaccine market due to improved healthcare infrastructure in this region. The North America paediatric vaccine market is expected to be valued at US$ 20.15 Bn by 2026 growing at a CAGR for 11.0%. In addition to North America, demand for paediatric vaccines has been significantly growing in Western Europe and APEJ. APEJ is expected to grow at a CAGR for 14.9% over the forecast period and is expected to dominate the market by 2026 by generating revenue of US$ 22.69 Bn and revenues in Western Europe are anticipated to grow by 11.2%. Middle East and Africa is expected to grow at a CAGR of 12.6% and this growth is anticipated by growth government intervention for immunisation by carrying out national level immunisation campaigns and also disease specific immunisation campaigns.

Request to View TOC @https://www.futuremarketinsights.com/askus/rep-gb-1317

Vendor insights

Key players in the global paediatric vaccine market include Indian Immunologicals, GlaaxoSmithKline Plc., Pfizer Inc., Sanofi, Merck & Co. Inc., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., and Bharat Biotech. The growth of paediatric vaccine market is attributed to the development in the research by key players in the field, for instance, in February 2016, GSK submitted US regulatory submission for expanding the indication of FLuLaval Quadrivalent, influenza vaccine, for infants more than 6 months. These developments will boost the growth of the global paediatric vaccine market.

Global Needle-free IV Connectors Market Analysis based on Healthcare Applications 2026

Needle-Free IV Connectors are needleless devices for connecting administration sets, syringes, and IV catheters. Depending on internal characteristic and functioning of the parts, connectors are classified as simple and complex. Simple connectors consist of stationary internal parts, whereas, complex connectors function according to the movement of internal parts. Simple connector’s category holds the majority of the products used in the healthcare delivery. The fluid displacement and fluid pathway are determined by the motion of the internal parts namely mechanical valve, which controls the movement and direction of the fluid in complex connectors. External characteristics such as housing, shape, and color for both the type may or may not be similar. The purpose of using needle-free IV connectors apart from the ease in infusion for both care providers and patients is to reduce the risk of needle-stick injuries among the health care providers and reducing the risk of bacterial and microbial contamination.

Some major players operating in the needle-free IV connectors market are Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CareFusion Corporation, ICU Medical, Inc., Nexus Medical LLC, RyMed Technologies, LLC, and Vygon SA.

Request Sample Copy Of This Research Report:

https://www.coherentmarketinsights.com/insight/request-sample/426

According to the World Health Organization (WHO), annually around 1 million deaths are associated with the improper use of syringes and needles, which can be prevented by using needle-free IV connectors. Harmful diseases namely hepatitis and HIV can spread through improper and reuse of needles and syringes. Unsafe use of injections accounts for 5% of HIV, 40% of Hepatitis C and 32% of Hepatitis B virus infections globally. Although needle stick injuries are uncommon they are a potential problem, which can prove to be serious and are also responsible for causing above mentioned diseases. According to the Centers for Disease Control and Prevention (CDC), needle stick injuries account for around 385,000 among healthcare workers in the U.S annually. The most important goal while employing IV administration sets and needle-free connectors is to reduce the manipulation factor as much as possible. Some of the U.S. Food & Drug Administration (FDA) approved needle-free IV connectors include One-Link, CARESITE, MaxPlus, and Kendall.

The global needle-free IV connectors market was valued at US$ 621.1 million in 2016 and is expected to reach a robust CAGR of 10.3% over the forecast period (2017-2025).

Needle free iv connector market

Rising incidence and prevalence of various chronic diseases and need for treatment is expected to boost the needle-free connectors market

North America accounts for the largest share in the global needle-free connectors market, followed by Europe. This is mainly attributed to the rise in the geriatric population and chronic diseases. According to the Centers for Disease Control and Prevention (CDC), 2016, about half of American adults, that is around 117 million people had one or more chronic health conditions and one in four adults had two or more chronic health conditions. The factors driving the growth of the needle-free IV connectors market includes government investments and funding to improve healthcare infrastructure, awareness in people, and healthcare practitioners. For instance, in 2013, the National Healthcare Safety Network (NHSN) and Center for Disease Control and Prevention (CDC) carried out surveillance methods to identify and track device-associated infections by setting the guidelines for the prevention of central-line associated bloodstream infections. Furthermore, according to the World Health Organization (WHO), in 2014, chronic diseases were the leading cause of mortality in Europe with over one-third of the European population above the age of 15 suffering with a chronic disease and two out of three people near 60 age had at least two chronic conditions.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/426

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Lymphocyte Activation Gene – 3 Protein Market Set for Rapid Growth and Trend, by 2026

Immune checkpoint receptors such as lymphocyte activation gene – 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene – 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene – 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene – 3 protein is associated with T cell exhaustion in which the T cells become desensitized and lose their ability to function.

LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene – 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.

Lymphocyte Activation Gene – 3 Protein Market Drivers

Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene – 3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.

Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date – August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period.

Lymphocyte Activation Gene – 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene – 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.


Lymphocyte Activation Gene – 3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene – 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2027


Lymphocyte Activation Gene 3 Protein Market Taxonomy

The global lymphocyte activation gene – 3 protein market is segmented on the basis of drug, cancer type, and region.


By Drug –

  • BMS-986016 (Relatlimab)
  • IMP321
  • IMP701
  • MGD013
  • Others

By Cancer Type –

  • Breast Cancer
  • Melanoma
  • Solid Tumors
  • Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Medical Holography Market to Expand at a Modest CAGR of 34% by 2026

The global medical holography market was valued at around US$ 240.0 Mn in 2017 and is anticipated to reach around US$ 3500.0 Mn by 2026, expanding at a CAGR of more than 30.0% from 2018 to 2026. Rise in prevalence of chronic diseases, such as cancer and cardiovascular events, increase in the geriatric population, and intensive research activities being performed to determine the various applications of holographic techniques in different surgical procedures are key factors that are estimated to propel the market during the forecast period.

Obtain Report Details @

https://www.transparencymarketresearch.com/medical-holography-market.html

Holographic technology is widely utilized for virtual display of images of the internal organs, heart, gastric organs, such as pancreas, liver, and the developing embryo for diagnosis of cancer and other chronic disease conditions. Applications of medical holography, such as medical imaging of different parts of body organs suspected of disease, possess potential for the medical holography market in the near future. Thus, further research in the field of medical holography for further utilization offers significant opportunities to the market in the near future.

The global medical holography market was valued around US$ 240 Mn in 2017. It is anticipated to expand at a stable CAGR of more than 34% between 2018 and 2026, according to a new report published by Transparency Market Research (TMR) titled “Medical holography market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. Expansion of the global medical holography market is expected to be driven by technological advancements and increasing usage of 3D medical imaging technology during the forecast period. The medical holography market in North America is expanding at a significant CAGR of above 30.0%, due to high prevalence of chronic diseases, advancements in the health care sector, and increased focus on research and developmental activities. 

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19295

Cancer was the second-leading cause of death, and in 2015, it was responsible for 8.8 million deaths worldwide. Helicobacter pylori infection is the best known carcinogen for gastric cancer. Most gastric cancer cases in Western countries are diagnosed at late stages, when the treatment remains less effective. Increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, has fueled the demand for diagnostic methods to detect cancer and cardiac diseases at an early stage. The progress of cancer depends upon its stage, and most advanced developments in diagnostics and medical holography technology and devices have therefore focused on early detection. These factors are expected to boost the medical holography market in the near future in order to identify chronic diseases such as cancers and cardiac disorders at an early stage.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19295

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

Sterilization Equipment and Disinfectant Market is Projected to Increment at a Healthy CAGR 4.5% Between 2018 and 2026

Globalization leads to the outbreak of several diseases, and some of them are lead to surgery. According to the annual plastic surgery procedural statistics, there were almost 15.9 million surgical and minimally-invasive cosmetic procedures performed in the U.S, in 2015, a 2% increase over 2014. This increasing number of surgeries is creating a demand for more sterilization of equipment in order to prevent any microbial infection. A large number of global manufacturers are putting constant efforts to develop and manufacture novel equipment so that the customer can carry out the sterilization process more effectively and smoothly. Demand for low temperature sterilization for moist and heat-sensitive equipment is rising. Key players are focusing on the development of new sterilization equipment and disinfectants with better efficacy. For instance, Becton, Dickinson and Company launched the Genesis, a low temperature rigid sterilization container system, which provides long-lasting protection and sterility maintenance for surgical instrumentation. These key developments are likely to augment the global sterilization equipment and disinfectant market in the near future. However, high price of sterilization equipment and increasing demand for disposable devices are likely to restrain the global sterilization equipment and disinfectant market during the forecast period.

Obtain Report Details @

https://www.transparencymarketresearch.com/sterilization-equipment-market.html

The global sterilization equipment and disinfectant market has been segmented based on method, disinfectant type, end-user and region. In terms of method, the heat sterilization segment is projected to dominate the market. However, the segment is expected to lose market share during the forecast period, due to fewer opportunities for new entrants in the segment. Moreover, the heat sterilization method is not suitable for heat and moist sensitive equipment, the sterilization process damages the equipment.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=389

Transparency Market Research (TMR) has published a new report titled ‘Sterilization Equipment and Disinfectant Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the new report, the global sterilization equipment and disinfectant market was valued above US$ 4,400 Mn in 2017. It is projected to expand at a CAGR of 4.5% from 2018 to 2026.

Rise in geriatric population leads to increase in the number of surgeries that are caused due to severe diseases and performed at hospitals and clinics and increase in number of hospital acquired infection are likely to boost the sterilization equipment and disinfectant market during the forecast period.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=389

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

Radiopharmaceutical Market is Projected to Increment at a Healthy CAGR 5.4%Between 2017 and 2024

The radiopharmaceutical market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on radioisotopes, source, end-user, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global radiopharmaceutical market.

Obtain Report Details @

https://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

The healthcare industry and medical professionals have played a huge role in enhancing the growth prospects of the market vendors. The distributors of radioactive drugs have also helped market players in reaching to wider audiences and expanding their consumer base. On account of the lucrative opportunities that float in the global radiopharmaceuticals market, several new names have made their way into the market. The new market vendors are expected to capitalise on tying up with distributors in order to stand better chances of growth.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

The global market for radiopharmaceuticals is expected to grow at a CAGR of 5.4% over the period between 2017 and 2024, finds Transparency Market Research (TMR). The global market for radiopharmaceuticals is prognosticated to accumulate revenues worth US$7,430.8 million by 2024, rising up from a value of US$5,145.1 million in 2017. On the basis of end user, hospitals have emerged as the largest consumer of radiopharmaceuticals. Based on geography, the demand for radiopharmaceuticals has been the highest in North America due to the presence of excellent research facilities in the region.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

Compounding Pharmacies Market to Reach US$ 2,479.4 thousand by 2021-End

Future Market Insights (FMI), in its latest report titled “Compounding Pharmacies Market: U.S. Industry Assessment and Forecast; 2015–2021”, has projected the U.S. compounding pharmacies market to expand at a CAGR of 5.7% during the forecast period (2015–2021).

Compounding pharmacies are pharmacies that produce drugs tailored to needs of individual patients, by altering, combining, or mixing active pharmaceutical ingredients of drugs. Compounded drugs are prepared under prescription from physicians. Compounding includes combination of two or more drug ingredients in varied proportions. Most regulatory agencies across the world do not approve compounded medications, and do not verify the safety or effectiveness of compounded drugs. These drugs are usually not reimbursed by pharmaceutical benefit agencies.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-us-978

Compounding pharmacies in the U.S. are estimated to account for market value of US$ 3,262.6 Mn by the end of 2015, and is projected to witness stable growth due to rising demand for personalized medicines from customers.    

The report analyses the U.S compounding pharmacies market in terms of market value (US$ Mn) by product, application and therapeutic area, and provides information regarding market dynamics, value chain, competitive landscape, current trends, market estimations and forecast.

The prime driver for the compounding pharmacies market is medicinal drought. Currently, there’s a shortage of over 300 drugs for various diseases in the U.S. When the need for critical drugs are not met through commercially-available branded equivalents, compounded drugs are sought after. Furthermore, increasing demand for anti-aging products that use custom compounded drugs is a prevalent trend across the globe. Innovative sub-therapeutic areas such as bio-identical hormone replacement therapy are also contributing to growing popularity of compounded drugs. 

On the basis of product type, the U.S. compounding pharmacies market is segmented into oral medication, topical medication, mouth washes, and suppositories.

Oral medications, constituting drugs that can be swallowed, are expected to exhibit stable growth rates ranging from 4.7% to 8.4% over 2015–2021.

Topical medications constitutes skin-application medications. Expected drivers for topical medication include rising popularity of innovative and promising personalized skin creams. Creams are most popular due to ease of preparation and also longer shelf-life. Ease of product composition even after combining two or three APIs customizes the drug and reduces manufacturing cost. Hence, price range varies significantly, i.e., from US$ 100 to 9,000 and above. Creams are mainly used for minimizing scars, skin irritations and other dermatological concerns and reducing pain at location, where oral dosages are not possible.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-us-978

Mouthwashes and suppositories are expected to witness slightly lower growth rates owing to formulation rigidity emerging from regulatory restrictions. Popularity of non-sterile products is projected to increase due to increased product safety regulations imposed by the U.S. FDA.

On the basis of application, the U.S. compounding pharmacies market is segmented into medications for adults, veterinary, children, and geriatric population. Among the different application areas, medication for adults is expected to register highest attractiveness index as compared to other application areas during the forecast period. Medication for adults constitute drugs for critical illnesses such as cardiovascular diseases and cancer. Medications for adults are expected to increase owing to more people adopting compounded drugs, as these can be customized as per needs of individual patients.

On the basis of therapeutic area, the U.S. compounding pharmacies market is segmented into pain management and hormone replacement therapy (HRT). Among the two therapeutic area segments, HRT is expected to register highest CAGR as compared to pain management during the forecast period. HRT is expected to gain popularity owing to increasing awareness across the world due to its various benefits associated with age-defying therapies and products to bettering individual health.

Get Full Report Now @ https://www.futuremarketinsights.com/checkout/978

Key market participants covered in the report include PharMEDium Services, LLC, Institutional Pharmacy Solutions, Cantrell Drug Company, and Triangle Compounding Pharmacies

Global Irritable Bowel Syndrome Treatment Market with present Situation and Forecast To 2026

The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.

Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.

Request Sample Copy Of This Research Report:

https://www.coherentmarketinsights.com/insight/request-sample/506

Market Dynamics

The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.

Market Taxonomy

This report segments the global irritable bowel syndrome treatment market on the basis of drug type, medical condition, and distribution channel. On the basis of drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.

Key features of the study:

This report provides in-depth analysis of irritable bowel syndrome treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global irritable bowel syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Abbott Laboratories*, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., Ironwood Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Irritable Bowel Syndrome Treatment Market

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/506

Detailed Segmentation:

Global Irritable Bowel Syndrome Treatment Market, By Drug Type:

Lubiprostone

Linaclotide

Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:

IBS-Constipation

IBS-Diarrhea

Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:

Hospital Pharmacies

Global Irritable Bowel Syndrome Treatment Market, By Geography:

North America

Europe

Asia-Pacific

Latin America

Middle East

Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Page 1 of 817

Powered by WordPress & Theme by Anders Norén